Clough Capital Partners L P reduced its position in Crispr Theraptc (NASDAQ:CRSP) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 824,864 shares of the company’s stock after selling 13,927 shares during the period. Crispr Theraptc comprises about 1.1% of Clough Capital Partners L P’s investment portfolio, making the stock its 27th largest position. Clough Capital Partners L P owned about 2.07% of Crispr Theraptc worth $17,919,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in CRSP. Franklin Resources Inc. purchased a new position in shares of Crispr Theraptc during the fourth quarter worth $14,389,000. Orbimed Advisors LLC purchased a new position in shares of Crispr Theraptc during the fourth quarter worth $7,541,000. Paulson & CO. Inc. purchased a new position in shares of Crispr Theraptc during the first quarter worth $1,099,000. Morgan Stanley raised its position in shares of Crispr Theraptc by 437.9% in the first quarter. Morgan Stanley now owns 20,526 shares of the company’s stock worth $447,000 after buying an additional 16,710 shares during the last quarter. Finally, Monashee Investment Management LLC raised its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the last quarter. Institutional investors own 24.08% of the company’s stock.
Shares of Crispr Theraptc (NASDAQ:CRSP) traded up 0.61% during trading on Tuesday, reaching $14.88. 84,307 shares of the company were exchanged. The firm’s market capitalization is $595.16 million. The company’s 50-day moving average is $15.49 and its 200 day moving average is $18.51. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The business had revenue of $2.70 million for the quarter. Equities research analysts expect that Crispr Theraptc will post ($2.41) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/06/20/crispr-theraptc-crsp-stake-reduced-by-clough-capital-partners-l-p.html.
Separately, Chardan Capital started coverage on shares of Crispr Theraptc in a report on Monday, March 27th. They issued a “buy” rating and a $23.50 price objective for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $23.10.
In related news, insider Samarth Kulkarni sold 11,615 shares of the firm’s stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $16.78, for a total transaction of $194,899.70. Following the completion of the transaction, the insider now owns 137,047 shares of the company’s stock, valued at $2,299,648.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Rodger Novak sold 3,650 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $15.02, for a total transaction of $54,823.00. Following the transaction, the chief executive officer now directly owns 1,218,655 shares of the company’s stock, valued at approximately $18,304,198.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 207,865 shares of company stock valued at $3,486,954. 39.98% of the stock is currently owned by corporate insiders.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.